On December 10, 2024, the Board of Directors (the “Board”) of Silexion Therapeutics Corp (the “Company”) appointed Professor Amnon Peled to the Board as an independent director. Professor Peled will serve for a term that lasts until the Company’s next annual general meeting, and will fill the Board seat vacated by Ilan Shiloah, who had resigned in September 2024.
Professor Peled will serve on each of the audit, compensation, and corporate governance and nominating committees of the Board, and has been affirmed by the Board to (i) be an “independent director” as defined by Nasdaq Listing Rule 5605(b)(1) and (ii) meet the further requirements for audit committee and compensation committee service contained in Nasdaq Listing Rules 5605(c)(2)(A) and 5605(d)(2)(A), respectively, including under Rules 10A-3 and 10C-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Professor Peled’s appointment to the audit committee is expected to remedy the Company’s Nasdaq listing deficiency related to the composition of the audit committee, by bringing to three the number of qualified directors serving on that committee. As previously disclosed, on November 19, 2024, the Company had been notified by The Nasdaq Stock Market LLC that, as a result of the resignation of Ilan Shiloah from the audit committee, the Company was not in compliance with Nasdaq’s audit committee composition requirements as set forth in Nasdaq Listing Rule 5605(c)(2)(A), which required the Company to have three qualified members of the audit committee.
Biographical information with respect to Professor Peled is set forth immediately below:
Amnon Peled, PhD, has served as an associate professor at Hadassah Medical Center, Jerusalem since August 2000. Professor Peled also served as Director of the Gene Therapy Institute at Hadassah Medical Center from October 2021 to February 2024. He specializes in cytokine research, hematopoietic stem cell biology, inflammation, and cancer, leading the development of therapies now in Phase II/III trials. Professor Peled served as Founder and CEO of Biokine Therapeutics, and as its Chief Scientific Officer, from July 2000 to February 2024, where he advanced the CXCR4 antagonist BKT140/BL8040. Prof. Peled is an author of over 100 publications and holder of 200+ patents and patent applications, and holds a Bachelor’s degree in agriculture from the Hebrew University of Jerusalem, a Master’s degree in cell biology and histology from Tel Aviv University, and a Ph.D. from the Weizmann Institute. He completed postdoctoral training at Harvard Medical School and the Weizmann Institute.
There are no arrangements or understandings between Prof. Peled and any other person pursuant to which he was selected as a director, and there have been no transactions since the beginning of the Company’s last fiscal year, nor are there any currently proposed transactions, regarding Prof. Peled that are required to be disclosed under Item 404(a) of Regulation S-K of the Securities and Exchange Commission.
On December 10, 2024, the Company issued a press release announcing Professor Peled’s appointment to the Board. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
| Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits
